Relieve GLP-1-related bowel irregularity and gastrointestinal discomfort like occasional gas, bloating, constipation and diarrhea
Of course, more long-term research is needed
Other integrated safety analyses have reported similar IRs of VTE in AA and AD, including baricitinib in AD (IR, 0.09/100 PY)32 and AA (IR, 0.1/100 PY),24 abrocitinib in AD (IR, 0.3/100 PY),33 and upadacitinib in AD (IRs, 0.3/100 PY [15mg], 0.2/100 PY [30mg]).25 EMA safety recommendations for JAK inhibitors (tofacitinib, baricitinib, upadacitinib, abrocitinib, filgotinib) do not include ritlecitinib.33 Additional long-term data are needed to assess VTE risk with selective JAK3/TEC inhibition in AA.25 Neuroaudiological events In chronic preclinical toxicology studies in dogs, reversible axonal dystrophy in the cerebellum was observed with ritlecitinib at exposures 7.4 times the approved human dose (50mg).25 At 33 times this dose, axonal dystrophy caused reversible hearing loss and alterations in brainstem auditory evoked potential (BAEP) waveforms
By integrating metabolic biomarkers with genomic and metabolomic data, personalized intervention strategies can be developed, particularly for patients with metabolic disorders
Bottom line is, neither the benefits nor the risks of the vast majority of these peptides have been scientifically proven in humans
